Search results for "Prostate"

showing 10 items of 621 documents

Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study

2020

Radium-223 has demonstrated efficacy in improving overall survival (OS) and in delaying symptomatic skeletal-related events (SREs). Bone Health Agents (BHA), i.e. RANK ligand inhibitor (Denosumab) and bisphosphonate such as zoledronic acid, are indicated to prevent SREs without a clear survival benefit. SREs on patient health have a high impact and it is, therefore, important to consider the role of new therapies with BHA to better understand the involvement of combination therapy. The primary aim of this multicentric study is to assess OS in mCRPC patients treated with Radium-223 in combination with BHA.430 consecutive patients treated with Radium-223 alone or in combination with BHA, affe…

MaleRadium-223Oncologymedicine.medical_specialtyRadium-223 dichlorideRadium-223 dichloride; bone health agents; mCRPC; overall survival; prostate canceroverall survivalBone healthBone and Bones030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineBone MarrowInternal medicinemedicineOverall survivalHumansRadiology Nuclear Medicine and imagingRadium-223 DichlorideNeoplasm MetastasisAgedL-Lactate DehydrogenaseRadiological and Ultrasound Technologybusiness.industrymCRPCAlkaline Phosphataseprostate cancermedicine.diseaseSurvival AnalysisRANK Ligand InhibitorProstatic Neoplasms Castration-ResistantDenosumabMulticenter studybone health agents030220 oncology & carcinogenesisSettore SECS-S/01businessRadiummedicine.drugInternational Journal of Radiation Biology
researchProduct

Radium-223 in mCPRC patients: a large real-life Italian multicenter study

2020

Background Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration. Methods 430 consecutive mCRPC patients were enrolled. Clinical data have been collected at baseline and at the end of the Radium-223 treatment. Furthermore, the overall survival(OS) of our population has been provided. Results 157 patients (36.5%) were still alive at the time of data analysis. A mean numbe…

MaleRadium-223radium-223; mCRPC; prostate cancer; target alpha therapyPediatricsmedicine.medical_specialtyradium-223UrologyPopulationBone NeoplasmsContext (language use)Quality of lifemedicineHumanseducationeducation.field_of_studybusiness.industrymCRPCprostate cancerProstatic Neoplasms Castration-ResistantRegimenSafety profileTreatment OutcomeItalyMulticenter studyNephrologyCohortQuality of LifeSettore SECS-S/01businesstarget alpha therapyRadiummedicine.drugMinerva Urology and Nephrology
researchProduct

Severe rectal bleeding after transrectal US-guided prostate biopsy. Case report

2006

CASE: The Authors report their experience about a case of severe rectal bleeding after transrectal ultrasound-guided prostate biopsy. INTERVENTION: After correct and sure diagnosis, the patient was submitted to resolutive endoscopic haemostatic treatment (failure of haemostatic mechanical manoeuvres, emergency colonscopy, haemostasis with sclerotherapy, heat bipolar probe and Argon Plasma Coagulation). RESULTS: Complete recovery (immediate stop bleeding). Follow-up (1 year) negative. CONCLUSIONS: Rectal bleeding after prostate biopsy is a important but rare complication of prostate cancer screening, potentially lethal. Best knowledge of causes and risk factors may improve the diagnosis and …

MaleRectal DiseasesBiopsy Needle Gastrointestinal Hemorrhage Prostate RectalBiopsy NeedleProstateRectumHumansMiddle AgedGastrointestinal HemorrhageSeverity of Illness IndexUltrasonography
researchProduct

Perineal complications following radical perineal prostatectomy.

2003

PURPOSE Radical perineal prostatectomy has recently attracted renewed interest and wider acceptance as an alternative route to the retropubic approach. While presumed lower morbidity is one reason for perineal prostatectomy we evaluated our patients for complications that are specific for the perineal approach. PATIENTS AND METHODS We have retrospectively analyzed 412 patients who underwent perineal prostatectomy from 10/1996 to 12/2000. Patients for the perineal approach were selected on the base of preoperative PSA (10 ng/ml) and biopsy Gleason score (< 7) without the need for simultaneous lymphadenectomy. A cystogram was performed routinely on day 7 p. o. and the catheter removed when pa…

MaleReoperationmedicine.medical_specialtyTime FactorsUrologymedicine.medical_treatmentFistulaBiopsyAnastomosisPerineumHematomaPostoperative ComplicationsmedicineHumansIntraoperative ComplicationsRetrospective StudiesProstatectomybusiness.industryUrinary retentionColostomyProstateProstatic NeoplasmsPerioperativeProstate-Specific Antigenmedicine.diseaseSurgeryCathetermedicine.symptombusinessRadical perineal prostatectomyAktuelle Urologie
researchProduct

Can We Clinically Distinguish Anejaculation From Retrograde Ejaculation in Patients on α1A-Blockers Therapy for Lower Urinary Tract Symptoms?

2019

To investigate the physiopathology of ejaculatory disorders (EjD) and discriminate between retrograde ejaculation (REj) and anejaculation (AEj) induced by α1A-blockers, through the association between the mean postorgasm seminal vesicle volume and the presence of sperm in midstream urine, in patients with moderate-to-severe lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement.Therapy-naïve male patients with LUTS and without previous EjD were treated with α1A-blockers. Pre- and post-treatment EjD were investigated through question 4 of the 4-item Male Sexual Function questionnaire and the Male Sexual Health Questionnaire for Ejaculatory Dysfunction Short Form (MSHQ-…

MaleRetrograde ejaculationmedicine.medical_specialtyEjaculationUrologymedia_common.quotation_subject030232 urology & nephrologyUrologyUrineUrineOrgasmSeminal vesicle volume03 medical and health sciences0302 clinical medicineSeminal vesicleLower Urinary Tract SymptomsLower urinary tract symptomsSurveys and QuestionnairesAlpha-blockermedicineLower urinary tract symptomHumansEjaculationCorrelation of DataOrgasmmedia_commonSperm Countbusiness.industryUrine sperm countProstateSeminal VesiclesOrgan SizeMiddle Agedmedicine.diseaseSpermSexual Dysfunction Physiologicalmedicine.anatomical_structure030220 oncology & carcinogenesisAdrenergic alpha-1 Receptor AntagonistsbusinessAnejaculationUrology
researchProduct

Sexual dysfunctions after transurethral resection of the prostate (TURP): evidence from a retrospective study on 264 patients

2015

Objectives: Benign prostatic hyperplasia (BPH) and sexual dysfunctions are diseases with a high prevalence in aged men. Several studies have found a link between BPH and LUTS resulting from deterioration in sexual function in men aged 50 years and older for whom TURP is considered the gold standard. The impact of TURP on sexual functions still remain uncertain, nor is it clear what pathophysiological mechanism underlying the emergence of new episodes of Erectile Dysfunction (ED) following TURP in patients with normal sexual function before surgery, while retrograde ejaculation and ejaculate volume reduction represent a clear side effect; derived from BPH treatment. The aim of this study was…

MaleRetrograde ejaculationmedicine.medical_specialtyLongitudinal studyUrologymedicine.medical_treatmentProstatic Hyperplasialcsh:RC870-923urologic and male genital diseasesPreoperative careSettore MED/24 - UrologiaErectile DysfunctionErectile Dysfunction (ED)Surveys and QuestionnairesInternal medicinePreoperative CaremedicineHumansInternational index of erectile function (IIEF)Longitudinal StudiesSicilyTransurethral resection of the prostate (TURP)AgedRetrospective StudiesTransurethral resection of the prostateAged 80 and overPostoperative CareLibidoBenign prostatic hyperplasiabusiness.industryBenign prostatic hyperplasia (BPH)Low urinary tract symptoms (LUTS).Transurethral Resection of ProstateTransurethral resection of the prostateRetrospective cohort studyMiddle Agedlcsh:Diseases of the genitourinary system. Urologymedicine.diseaseInternational index of erectile functionLow urinary tract symptomsSurgeryErectile dysfunctionSexual functionbusinessArchivio Italiano di Urologia e Andrologia
researchProduct

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

2007

Microscopic foci of prostatitis may induce prostate-specific antigen (PSA) increase. PSA reduction after antibiotics might identify those patients in whom biopsy can be avoided. Ninety-nine patients received ciprofloxacin for 3 weeks, of whom 59 showed PSA reduction. Histology detected small foci of prostatitis in 65% of cases. Carcinoma was found in 40 and 20.3% of patients with unchanged or decreased PSA, respectively (P=0.03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml.

MaleRiskCancer Researchmedicine.medical_specialtyTime FactorsProstate biopsymedicine.drug_classUrologyAntibioticsUrologyProstatitisUnnecessary Proceduresurologic and male genital diseasesSettore MED/24 - UrologiaDiagnosis DifferentialProstate cancerCiprofloxacinBiopsyCarcinomaHumansMedicineUltrasonography InterventionalAgedAged 80 and overPalpationmedicine.diagnostic_testbusiness.industryPatient SelectionBiopsy NeedleProstateProstatic NeoplasmsCancerHistologyOrgan SizeMiddle AgedProstate-Specific Antigenmedicine.diseaseAnti-Bacterial AgentsProstatitisOncologybusinessprostate-specific antigen (PSA) prostatitis prostate carcinomaFollow-Up Studies
researchProduct

Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies

2020

Multiple studies have suggested that ω-3 fatty acid intake may have a protective effect on cancer risk; however, its true association with cancer risk remains controversial. We performed an umbrella review of meta-analyses to summarize and evaluate the evidence for the association between ω-3 fatty acid intake and cancer outcomes. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to December 1, 2018. We included meta-analyses of observational studies that examined associations between intake of fish or ω-3 fatty acid and cancer risk (gastrointestinal, liver, breast, gynecologic, prostate, brain, lung, and skin) and determined the level of evidence of…

MaleRiskOncologymedicine.medical_specialty[SDV]Life Sciences [q-bio]BFMedicine (miscellaneous)ReviewCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerω-3 fatty acidMeta-Analysis as TopicNeoplasmsInternal medicineFatty Acids Omega-3medicineAnimalsHumanscancer030212 general & internal medicineω-3 fatty acid fish cancer umbrella review meta-analysischemistry.chemical_classificationfishNutrition and Dieteticsumbrella reviewbusiness.industryEndometrial cancerFishesFatty acidCancermedicine.diseaseR13. Good healthmeta-analysisObservational Studies as TopicchemistryCase-Control Studies030220 oncology & carcinogenesisMeta-analysisFemaleSkin cancerbusinessLiver cancerFood Science
researchProduct

Evaluation of prostate segmentation algorithms for MRI: The PROMISE12 challenge

2014

Contains fulltext : 137969.pdf (Publisher’s version ) (Open Access) Prostate MRI image segmentation has been an area of intense research due to the increased use of MRI as a modality for the clinical workup of prostate cancer. Segmentation is useful for various tasks, e.g. to accurately localize prostate boundaries for radiotherapy or to initialize multi-modal registration algorithms. In the past, it has been difficult for research groups to evaluate prostate segmentation algorithms on multi-center, multi-vendor and multi-protocol data. Especially because we are dealing with MR images, image appearance, resolution and the presence of artifacts are affected by differences in scanners and/or …

MaleScannerObserver (quantum physics)Computer scienceHealth InformaticsSensitivity and SpecificityArticleProstate cancerSegmentationImaging Three-DimensionalRobustness (computer science)Image Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingSegmentationChallengeProtocol (science)Modality (human–computer interaction)Radiological and Ultrasound TechnologyProstateProstatic NeoplasmsReproducibility of ResultsReference Standardsmedicine.diseaseImage EnhancementComputer Graphics and Computer-Aided DesignMagnetic Resonance ImagingActive appearance modelUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Computer Vision and Pattern RecognitionArtifactsAlgorithmAlgorithmsRare cancers Radboud Institute for Health Sciences [Radboudumc 9]MRI
researchProduct

Evaluation of Deep Neural Networks for Semantic Segmentation of Prostate in T2W MRI

2020

In this paper, we present an evaluation of four encoder&ndash

MaleSimilarity (geometry)Computer scienceSegNet02 engineering and technologylcsh:Chemical technologyBiochemistryArticleencoder–decoder030218 nuclear medicine & medical imagingAnalytical Chemistry03 medical and health sciencesProstate cancer0302 clinical medicineProstateImage Processing Computer-Assisted0202 electrical engineering electronic engineering information engineeringmedicineHumanslcsh:TP1-1185SegmentationElectrical and Electronic EngineeringInstrumentationmedicine.diagnostic_testPixelbusiness.industryProstateCNNsPattern recognitionMagnetic resonance imagingFCNmedicine.diseaseMagnetic Resonance ImagingU-NetAtomic and Molecular Physics and OpticsSemanticsIntensity normalizationmedicine.anatomical_structureDeepLabV3+Deep neural networks020201 artificial intelligence & image processingNeural Networks ComputerArtificial intelligencebusinessDNNSensors
researchProduct